Stay updated with breaking news from Randomized Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This randomized clinical trial evaluates the benefits and risks of the addition of a P2Y12 inhibitor to anticoagulant therapy compared with anticoagulant therap
Because venous and arterial thromboembolism are common among patients hospitalized with COVID-19, anticoagulant therapies were among the first to be evaluated i
RECOVERY results do not support aspirin use in this setting Treatment with aspirin did not bring about any clinically meaningful improvements in outcomes among patients hospitalized with Covid-19 in the large, randomized, open-label RECOVERY trial. Aspirin was not associated with reductions in 28-day mortality or in the risk of progression to invasive mechanical ventilation in
Study finds that compared with standard care, aspirin therapy did not significantly decrease the risk for all-cause mortality, invasive mechanical ventilation, renal dialysis, or hemofiltration among patients hospitalized with COVID-19.
This narrative review discusses what is currently known about the pathophysiology, epidemiology, diagnosis, management, prognosis, and prevention of coronavirus